Stock listing
NASDAQ:OABI OmniAb, Inc. Stock
Home listing (NASDAQ) of OmniAb, Inc.
Follow OmniAb, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:OABI
$4.66 USD -0.42 (-8.3%)
Close on Nov 20, 2026
- Day range
- $4.61 – $5.05 USDNov 20, 2026
- Volume
- 1.90M sharesNov 20, 2026
- Market cap
- $679.7M USDAt the close on Nov 20, 2026 · price × 145.9M shares outstanding
- 52-week range
- $1.35 – $5.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.99M USDMedian day 1.34M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OABI · Home | $4.66 USD | -0.42 (-8.3%) | 1,898,284 | $4.90 | $5.05 | $4.61 | $5.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OABI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.66 | -0.42 | -8.3% | $4.90 | $5.05 | $4.61 | 1,898,284 | |
| $5.08 | +0.03 | +0.6% | $5.05 | $5.174 | $5.00 | 1,215,073 | |
| $5.05 | +0.16 | +3.3% | $4.89 | $5.07 | $4.80 | 1,263,886 | |
| $4.89 | -0.02 | -0.4% | $4.85 | $4.935 | $4.73 | 1,234,643 | |
| $4.91 | -0.04 | -0.8% | $4.95 | $4.97 | $4.85 | 851,738 | |
| $4.95 | -0.15 | -2.9% | $5.065 | $5.08 | $4.73 | 1,403,267 | |
| $5.10 | 0.00 | 0.0% | $5.10 | $5.20 | $5.035 | 789,290 | |
| $5.10 | -0.20 | -3.8% | $5.25 | $5.35 | $4.855 | 1,754,350 | |
| $5.30 | +0.27 | +5.4% | $5.116 | $5.45 | $5.01 | 2,467,366 | |
| $5.03 | +0.20 | +4.1% | $4.86 | $5.215 | $4.86 | 1,442,252 | |
| $4.83 | -0.35 | -6.8% | $5.18 | $5.20 | $4.795 | 1,246,045 | |
| $5.18 | +0.03 | +0.6% | $5.285 | $5.36 | $5.00 | 1,142,445 | |
| $5.15 | +0.06 | +1.2% | $5.12 | $5.37 | $5.015 | 1,557,337 | |
| $5.09 | -0.02 | -0.4% | $5.11 | $5.31 | $4.935 | 2,148,641 | |
| $5.11 | -0.12 | -2.3% | $4.40 | $5.11 | $4.39 | 2,110,453 | |
| $5.23 | -0.05 | -0.9% | $5.37 | $5.405 | $5.14 | 1,677,670 | |
| $5.28 | +0.32 | +6.5% | $4.92 | $5.29 | $4.905 | 1,582,653 | |
| $4.96 | +0.35 | +7.6% | $4.61 | $4.98 | $4.549 | 1,113,208 | |
| $4.61 | -0.05 | -1.1% | $4.66 | $4.72 | $4.53 | 971,627 | |
| $4.66 | -0.12 | -2.5% | $4.70 | $4.785 | $4.515 | 1,283,200 | |
| $4.78 | -0.135 | -2.7% | $4.91 | $5.055 | $4.71 | 1,336,600 | |
| $4.915 | -0.045 | -0.9% | $4.96 | $5.132 | $4.80 | 3,176,500 | |
| $4.96 | +0.27 | +5.8% | $4.74 | $5.105 | $4.74 | 1,930,800 | |
| $4.69 | +0.10 | +2.2% | $4.53 | $4.755 | $4.52 | 892,400 | |
| $4.59 | -0.14 | -3.0% | $4.73 | $4.82 | $4.505 | 969,400 | |
| $4.73 | +0.18 | +4.0% | $4.60 | $4.755 | $4.531 | 820,500 | |
| $4.55 | -0.15 | -3.2% | $4.62 | $4.83 | $4.53 | 737,800 | |
| $4.70 | -0.07 | -1.5% | $4.76 | $4.815 | $4.62 | 809,400 | |
| $4.77 | -0.02 | -0.4% | $4.77 | $4.845 | $4.64 | 988,600 | |
| $4.79 | +0.13 | +2.8% | $4.66 | $4.915 | $4.59 | 1,038,100 | |
| $4.66 | +0.10 | +2.2% | $4.41 | $4.66 | $4.215 | 1,529,500 | |
| $4.56 | +0.21 | +4.8% | $4.35 | $4.75 | $4.30 | 1,498,200 | |
| $4.35 | -0.57 | -11.6% | $4.85 | $5.00 | $4.215 | 2,002,200 | |
| $4.92 | +0.05 | +1.0% | $4.83 | $5.02 | $4.64 | 1,215,100 | |
| $4.87 | -0.12 | -2.4% | $5.04 | $5.09 | $4.81 | 1,623,600 | |
| $4.99 | +0.03 | +0.6% | $4.94 | $5.055 | $4.835 | 1,981,600 | |
| $4.96 | +0.22 | +4.6% | $4.76 | $5.05 | $4.72 | 1,928,700 | |
| $4.74 | 0.00 | 0.0% | $4.74 | $4.95 | $4.615 | 1,391,900 | |
| $4.74 | +0.13 | +2.8% | $4.61 | $4.81 | $4.55 | 674,900 | |
| $4.61 | -0.18 | -3.8% | $4.82 | $4.84 | $4.585 | 783,600 | |
| $4.79 | 0.00 | 0.0% | $4.75 | $4.865 | $4.63 | 1,044,800 | |
| $4.79 | -0.13 | -2.6% | $4.90 | $4.995 | $4.685 | 1,050,100 | |
| $4.92 | +0.34 | +7.4% | $4.61 | $4.93 | $4.545 | 1,375,000 | |
| $4.58 | +0.11 | +2.5% | $4.50 | $4.64 | $4.45 | 1,363,900 | |
| $4.47 | +0.03 | +0.7% | $4.43 | $4.50 | $4.30 | 1,862,000 | |
| $4.44 | +0.09 | +2.1% | $4.44 | $4.455 | $4.25 | 984,000 | |
| $4.35 | 0.00 | 0.0% | $4.38 | $4.45 | $4.27 | 1,064,600 | |
| $4.35 | -0.13 | -2.9% | $4.43 | $4.43 | $4.24 | 788,700 | |
| $4.48 | +0.41 | +10.1% | $4.13 | $4.535 | $4.12 | 1,599,200 | |
| $4.07 | +0.12 | +3.0% | $3.97 | $4.11 | $3.89 | 1,315,800 | |
| $3.95 | -0.065 | -1.6% | $3.922 | $4.075 | $3.91 | 1,393,700 | |
| $4.015 | -0.225 | -5.3% | $4.21 | $4.27 | $3.97 | 1,203,300 | |
| $4.24 | -0.09 | -2.1% | $4.30 | $4.33 | $4.135 | 1,272,300 | |
| $4.33 | -0.42 | -8.8% | $4.78 | $4.78 | $4.28 | 1,703,500 | |
| $4.75 | -0.29 | -5.8% | $5.08 | $5.08 | $4.625 | 2,004,600 | |
| $5.04 | +0.60 | +13.5% | $4.47 | $5.43 | $4.47 | 5,082,600 | |
| $4.44 | +0.06 | +1.4% | $4.35 | $4.45 | $4.32 | 1,155,200 | |
| $4.38 | -0.09 | -2.0% | $4.44 | $4.46 | $4.33 | 1,179,200 | |
| $4.47 | -0.14 | -3.0% | $4.54 | $4.58 | $4.415 | 1,297,100 | |
| $4.61 | -0.20 | -4.2% | $4.81 | $4.81 | $4.56 | 1,282,700 | |
| $4.81 | +0.15 | +3.2% | $4.695 | $4.93 | $4.635 | 1,442,200 | |
| $4.66 | -0.05 | -1.1% | $4.68 | $4.78 | $4.58 | 1,467,054 | |
| $4.71 | +0.38 | +8.8% | $4.40 | $4.71 | $4.20 | 1,941,317 | |
| $4.33 | +0.03 | +0.7% | $4.31 | $4.535 | $4.14 | 1,851,700 | |
| $4.30 | +0.11 | +2.6% | $4.188 | $4.59 | $4.16 | 2,253,100 |
- Ticker
- NASDAQ:OABI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 30, 2026
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
Latest earnings call · Oct 30, 2026
OmniAb (NASDAQ:OABI) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 30, 2026
Q3 2026 Earnings Presentation
Earnings · 27 slides
Latest news
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
Oct 30, 2026
Closed $5.11 (-2.3%) on Oct 30, 2026
OmniAb to Participate in Upcoming Investor Conferences in November
Oct 26, 2026
Closed $4.96 (+7.6%) on Oct 27, 2026
OmniAb to Report Third Quarter 2026 Financial Results on October 30
Oct 14, 2026
Closed $4.73 (+4.0%) on Oct 15, 2026
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Oct 6, 2026
Closed $4.35 (-11.6%) on Oct 6, 2026
OmniAb to Participate in Upcoming Investor Conferences
Aug 26, 2026
Closed $4.81 (+3.2%) on Aug 26, 2026
OmniAb Raises 2026 Financial Guidance
Aug 17, 2026
Closed $3.82 (+13.0%) on Aug 17, 2026
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 6, 2026
Closed $3.08 (+37.5%) on Aug 7, 2026
OmniAb to Report Second Quarter 2026 Financial Results on August 6
Jul 16, 2026
Closed $2.04 (-1.9%) on Jul 16, 2026
OmniAb Names Amechi Nwachuku Chief Operating Officer
Jul 13, 2026
Closed $2.11 (-7.9%) on Jul 13, 2026
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Closed $1.66 (+12.9%) on May 8, 2026
OmniAb, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 17 in the last 12 months · 53 in all · newest Oct 30, 2026 · oldest 2022
- Calls
- 16 calls with a replay · 16 with a transcript · latest Oct 30, 2026
- Decks
- 40 decks · latest Oct 30, 2026
Where OmniAb, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OABI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:OABI | BOATS | United States | USD |
Valuation
EV/sales 15.3× against a median of 3.6×: the highest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $615.5M USD
- P/E
- Loss
- EV/sales
- 15.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.7×
- Gross margin
- Not reported
- Operating margin
- −115.9%
- Net margin
- −108.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.29
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| OmniAb, Inc. · NASDAQ:OABI | US$679.7M | US$615.5M | n/a | 15.3× | n/a | 2.7× | −108.1% | 0.0× | 1.29 |
| HOB Biotech Group Corp., Ltd. Class A · SSE:688656 | US$800.9M | US$789.4M | 204× | 12.8× | n/a | 6.3× | 6.3% | 0.0× | n/a |
| Cytek Biosciences, Inc. · NASDAQ:CTKB | US$800.4M | US$569.2M | n/a | 2.7× | n/a | 2.5× | −39.1% | 0.1× | 0.79 |
| Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class A · SSE:688621 | US$769.9M | US$694.3M | n/a | 4.6× | n/a | 4.2× | −0.2% | 0.0× | n/a |
| Oxford BioMedica plc · LSE:OXB | US$767.3M | US$876.3M | n/a | 4.0× | n/a | 10.1× | −17.8% | 2.7× | n/a |
| Beijing Hotgen Biotech Co. Ltd. Class A · SSE:688068 | US$758.2M | US$598.0M | n/a | 8.4× | n/a | 2.1× | −65.6% | 0.0× | n/a |
| Maccura Biotechnology Co., Ltd. Class A · SZSE:300463 | US$722.4M | US$677.6M | n/a | 2.1× | n/a | 0.8× | −1.5% | 0.1× | n/a |
| R&G PharmaStudies Co., Ltd. Class A · SZSE:301333 | US$706.0M | US$456.1M | 40.4× | 3.2× | n/a | 2.4× | 12.2% | 0.0× | n/a |
| SD Biosensor, Inc. · KRX:137310 | US$655.8M | US$520.0M | n/a | 0.9× | 11.5× | 0.4× | −98.8% | 0.1× | n/a |
| PharmaResources (Shanghai) Co., Ltd Class A · SZSE:301230 | US$641.2M | US$600.8M | 149× | 5.5× | n/a | 4.2× | 4.0% | 0.0× | n/a |
| Getein Biotech, Inc. Class A · SSE:603387 | US$608.2M | US$358.4M | 13.8× | 2.1× | n/a | 1.4× | 26.3% | 0.0× | n/a |
| Median of the others | US$740.3M | US$599.4M | 94.9× | 3.6× | 11.5× | 2.4× | −0.8% | 0.0× | 0.79 |
Forecasts
7 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.35 · 5 analysts
- Revenue, year to Dec 2026
- 37.07M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Matthew W. Foehr | President and Chief Executive Officer |
| Kurt Gustafson | Chief Financial Officer |
| Amechi Nwachuku | Chief Operating Officer |
| Charles Berkman | Chief Legal Officer |
| Ellen Smith | Associate General Counsel, Intellectual Property and Licensing |
| Bill Harriman | Sr. Vice President, Discovery Partnership Management, Technology Development and Operations |
| Bob Chen | Sr. Vice President, Discovery Systems |
| Chris Silvia | Vice President, Data Sciences and Corporate IT |
| Christel Iffland | Sr. Vice President, R&D Portfolio Management and Technology Operations |
| Cia McCaffrey | Sr. Vice President, People and Talent |
| Neil Castle | Vice President, Biology |
| Todd Pettingill | Vice President, Business Development and Strategy |
| Yasmina Abdiche | Sr. Vice President, Exploratory Research |
Board
| Director | Role |
|---|---|
| John Higgins | Board Chair |
| Carolyn R. Bertozzi | Board Member |
| Jennifer Cochran | Board Member |
| Matthew W. Foehr | President and Chief Executive Officer |
| Philip J. Gotwals | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| OmniAb (NASDAQ:OABI) Q3 2026 Earnings Call | Fri, Oct 30, 2026 · 8:00 AM ET | Replay |
| OmniAb (NASDAQ:OABI) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q4 2025 Earnings Call | Wed, Mar 04, 2026 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q4 2024 Earnings Call | Tue, Mar 18, 2025 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| OmniAb (NASDAQ:OABI) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q4 2023 Earnings Call | Wed, Mar 20, 2024 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 11:00 AM ET | Replay |
| OmniAb (NASDAQ:OABI) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 4:30 PM ET | Replay |
| OmniAb (NASDAQ:OABI) Q1 2023 Earnings Call | Thu, May 11, 2023 · 8:30 AM ET | Replay |
| OmniAb (NASDAQ:OABI) Q4 2022 Earnings Call | Thu, Mar 30, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · Before open | −2.3% |
| Q2 2026 | Aug 6, 2026 · After close | +37.5% |
| Q1 2026 | May 7, 2026 · After close | +12.9% |
| Q4 2025 | Mar 5, 2026 | +4.4% |
| Q3 2025 | Nov 4, 2025 · After close | −3.7% |
| Q2 2025 | Aug 6, 2025 · After close | −2.6% |
| Q1 2025 | May 8, 2025 · After close | −8.3% |
| Q4 2024 | Mar 18, 2025 · After close | −20.4% |
| Q3 2024 | Nov 12, 2024 · After close | −9.3% |
| Q2 2024 | Aug 8, 2024 · After close | −1.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +2.4% |
| Q4 2023 | Mar 20, 2024 · After close | −5.2% |
| Q3 2023 | Nov 9, 2023 · Before open | −4.2% |
| Q2 2023 | Aug 10, 2023 · After close | −5.5% |
| Q1 2023 | May 11, 2023 · After close | +8.4% |
| Q4 2022 | Mar 30, 2023 · After close | +4.8% |
| Q3 2022 | Nov 10, 2022 · After close | −2.3% |
| Q2 2022 | Aug 12, 2022 · After close | +0.2% |
| Q1 2022 | May 20, 2022 · After close | −0.1% |
| Quarter to Dec 31, 2021 | Mar 28, 2022 · After close | −0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 27 slides | Oct 30, 2026 |
| Investor Day (October 2026) | Investor day | 69 slides | Oct 6, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 24 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 22 slides | May 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Mar 4, 2026 |
| AETC Scientific Briefing 2025 | Conference | 25 slides | Dec 16, 2025 |
| AETC 2025 Scientific Briefing #6 | Conference | 21 slides | Dec 15, 2025 |
| Jefferies Global Healthcare Conference London 2025 | Conference | 25 slides | Nov 19, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 24 slides | Nov 4, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 20 slides | Aug 6, 2025 |
All 40 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$30M · US$1.4 a share · Leerink Partners Dealers: Leerink Partners (lead) Insiders: Officers and directors participate at $1.85 per share Use of proceeds: General corporate purposes | Aug 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Avista Public Acquisition Corp. II, a blank check company (SPAC). Priced at US$10.00 a unit on Aug 9, 2021.
- Price
- US$10.00 a unit
- Units offered
- 20,000,000 units
- Offering size
- US$200 million
- Underwriters' option
- Up to 3,000,000 more units
- Listing
- AHPAU on Nasdaq
- Underwriter
- Credit Suisse
- Units delivered
- On or about Aug 12, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 19, 2021 |
| Filed publicly | Jun 17, 2021 |
| Amended once | Jul 28, 2021 |
| Shares registered with an exchange | Aug 9, 2021 |
| Declared effective by the SEC | Aug 9, 2021 |
| Final prospectus, with the price | Aug 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 11, 2021 |
| CERT · Exchange's certificate of listing | Aug 10, 2021 |
| EFFECT · Notice that a registration is effective | Aug 9, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 9, 2021 |
| CORRESP · Letter to the SEC | Aug 5, 2021 |
| CORRESP · Letter to the SEC | Aug 5, 2021 |
| CORRESP · Letter to the SEC | Jul 28, 2021 |
| S-1/A · Registration statement, amended | Jul 28, 2021 |
| UPLOAD · Letter from the SEC | Jul 6, 2021 |
| S-1 · Registration statement | Jun 17, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | May 12, 2021 |
| DRS/A · Draft registration statement, amended | May 12, 2021 |
| UPLOAD · Letter from the SEC | Apr 14, 2021 |
| DRS · Draft registration statement | Mar 19, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.7M | 26.4M | 34.2M | 59.1M | 34.7M |
| Research and development | 47.8M | 55.1M | 56.5M | 48.4M | 39.2M |
| Operating income | -69.0M | -74.5M | -69.4M | -26.6M | -35.6M |
| Depreciation and amortization | 21.8M | 23.6M | 19.5M | 18.2M | 16.3M |
| EBITDA | -47.2M | -50.9M | -49.9M | -8.40M | -19.4M |
| Interest expense | 0 | 7.00K | |||
| Income before tax | -66.3M | -71.4M | -64.4M | -26.1M | -34.4M |
| Income tax | -1.51M | -9.38M | -13.7M | -3.73M | -7.31M |
| Net income | -64.8M | -62.0M | -50.6M | -22.3M | -27.0M |
| Earnings per share, basic | -0.57 | -0.61 | -0.51 | -0.26 | -0.33 |
| Earnings per share, diluted | -0.57 | -0.61 | -0.51 | -0.26 | -0.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 25.5M | 27.6M | 16.4M | 33.4M | 0 |
| Short-term investments | 28.5M | 31.8M | 70.6M | 54.9M | 0 |
| Receivables | 7.39M | 5.27M | 3.84M | 30.3M | 21.1M |
| Inventory | 823.0K | 48.0K | |||
| Current assets | 65.3M | 68.1M | 94.9M | 125.0M | 22.5M |
| Property, plant and equipment | 9.43M | 15.5M | 18.2M | 20.0M | 6.79M |
| Goodwill | 84.0M | 84.0M | 84.0M | 84.0M | 84.0M |
| Total assets | 300.9M | 325.6M | 375.2M | 421.2M | 304.5M |
| Accounts payable | 1.88M | 2.30M | 4.41M | 2.97M | 2.92M |
| Current liabilities | 16.3M | 15.1M | 23.1M | 26.0M | 20.6M |
| Total liabilities | 33.9M | 37.9M | 60.6M | 79.8M | 70.2M |
| Shareholders' equity | 267.0M | 287.6M | 314.6M | 341.4M | 234.3M |
| Shares outstanding | 144.3M | 121.6M | 116.9M | 115.2M | 0 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -36.5M | -39.7M | 2.35M | -3.59M | -5.67M |
| Capital spending | -565.0K | -1.88M | -1.64M | -17.2M | -4.07M |
| Free cash flow | -37.0M | -41.5M | 703.0K | -20.8M | -9.74M |
| Cash from investing | 6.47M | 37.9M | -18.4M | -73.3M | -4.03M |
| Cash from financing | 27.9M | 13.0M | -892.0K | 110.7M | 9.70M |
| Change in cash | -2.07M | 11.2M | -16.9M | 33.8M | 0 |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 16, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 12, 2025 | Offer document | SEC |
| D | Sep 10, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 24, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 19, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 19, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 14, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 13, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2023 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Dec 8, 2023 | Offer document | SEC |
| S-3 · Registration statement | Dec 8, 2023 | Offer document | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 9, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 2, 2023 | Offer document | SEC |
| 3 · Initial statement of ownership | Nov 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 1, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 10, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
This page holds 200 of 387 filings. Open Filings
Cap table
Built by 6ix from OmniAb, Inc.’s releases · as of Oct 23, 2026
- Common shares
- 145,860,318
- Fully diluted
- 145,860,318
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 145,860,318 | Oct 23, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 23, 2026 | 145,860,318 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sarah Boyce Other companies: Atrium Therapeutics, Inc. (Chair · Since at least Feb 26, 2026); Contineum Therapeutics, Inc. (Director · Since at least Jun 24, 2024); Avidity Biosciences, Inc (President and CEO, Director · Since at least Jun 11, 2020); Berkeley Lights Inc (Director · Jul 16, 2020 – May 14, 2021 · Past); Ligand Pharmaceuticals Incorporated (Director · Oct 15, 2019 – Jun 10, 2022 · Past); Akcea Therapeutics Inc (President, Director · Apr 17, 2018 – Jul 15, 2019 · Past); Ionis Pharmaceuticals, Inc. (Chief Business Officer · Jan 1, 2015 – Jan 15, 2018 · Past) | Director · Nov 1, 2022 – Jun 18, 2024 · Past |
| David F Burgstahler Other companies: Organogenesis Holdings Inc. (Director · Aug 17, 2018 – May 14, 2021 · Past); WideOpenWest Inc (Director · May 24, 2017 – Aug 6, 2019 · Past); Lantheus Holdings, Inc. (Director · Nov 21, 2016 – Sep 7, 2017 · Past); Syneos Health Inc (Director · Aug 24, 2016 – May 23, 2017 · Past); AngioDynamics, Inc. (Director · Jul 22, 2015 – Apr 12, 2017 · Past) | Director · Aug 9, 2021 – Jun 18, 2024 · Past |
| Kurt Gustafson Other companies: Xencor, Inc. (Director · Since at least Jul 14, 2014); Niagen Bioscience, Inc. (Director · Oct 21, 2016 – Jun 17, 2021 · Past); Spectrum Pharmaceuticals Inc (EVP & Chief Financial Officer · Jun 3, 2013 – Mar 15, 2022 · Past); Halozyme Therapeutics, Inc. (Vice President and CFO · Apr 13, 2009 – Feb 4, 2013 · Past) | Chief Financial Officer · Since at least Nov 1, 2022 |
| John Higgins Other companies: Immunome, Inc. (Chief Scientific Officer · Since at least Oct 2, 2023); Bio-Techne Corp (Director · Since at least Jun 4, 2019); Ligand Pharmaceuticals Incorporated (Director · May 14, 2019 – Dec 28, 2022 · Past) | Board Chair · Since at least Nov 1, 2022 |
| Matthew W. Foehr Other companies: Viking Therapeutics, Inc. (Director · Since at least Apr 13, 2016); AIxCrypto Holdings, Inc. (Director · Nov 29, 2016 – Jan 21, 2020 · Past); Ligand Pharmaceuticals Incorporated (President and COO · Aug 5, 2016 – Jun 10, 2022 · Past) | President and Chief Executive Officer · Since at least Nov 1, 2022 |
| Thompson Dean Other companies: Hi-Crush Partners LP (Director · Aug 23, 2018 – Aug 23, 2018 · Past); Organogenesis Holdings Inc. (Director · Aug 17, 2018 – May 14, 2021 · Past); VWR Corp (Director · Oct 1, 2014 – Oct 7, 2014 · Past) | Director · Aug 9, 2021 – Jun 18, 2024 · Past |
| William E Klitgaard Other companies: Zapata Quantum, Inc. (Director · Since at least Mar 28, 2024); Syneos Health Inc (Director · Mar 1, 2017 – Sep 28, 2023 · Past); Covance Inc (Corporate Sr. Vice President · Feb 23, 2006 – Feb 19, 2015 · Past) | Director · Aug 9, 2021 – Aug 9, 2021 · Past |
| Carolyn R. Bertozzi Other companies: Eli Lilly and Company (Director · Since at least Nov 16, 2020); Alnylam Pharmaceuticals, Inc. (Director · Jan 5, 2023 – May 8, 2025 · Past) | Director · Since at least Nov 1, 2022 |
| Charles C Harwood Jr Other companies: Organogenesis Holdings Inc. (Director · Oct 7, 2016 – Dec 10, 2018 · Past); Syneos Health Inc (Director · Nov 6, 2014 – Aug 24, 2016 · Past) | Director · Aug 24, 2022 – Aug 24, 2022 · Past |
| Benjamin Silbert Other companies: Organogenesis Holdings Inc. (General Counsel and Secretary · Oct 7, 2016 – Oct 7, 2016 · Past) | General Counsel · Aug 9, 2021 – Aug 9, 2021 · Past |
All 30 people
| Person | Seat |
|---|---|
| Jennifer Cochran Other companies: Ligand Pharmaceuticals Incorporated (Director · Jul 12, 2021 – Jun 10, 2022 · Past) | Board Member · Since at least Nov 1, 2022 |
| John Cafasso Other companies: Organogenesis Holdings Inc. (Chief Financial Officer · Oct 7, 2016 – Oct 7, 2016 · Past) | Chief Financial Officer · Aug 9, 2021 – Aug 9, 2021 · Past |
| Philip J Gotwals Other companies: Capricor Therapeutics, Inc. (Director · Since at least Jul 21, 2023) | Director · Since at least Apr 21, 2025 |
| Philip J. Gotwals Other companies: Capricor Therapeutics, Inc. (Director · Since at least Nov 4, 2026) | Board Member · Since at least May 8, 2025 |
| Steven C Crouse Other companies: Bio-Techne Corp (President - Diag & Spatial Bi · Since at least Mar 1, 2026) | Director · Since at least Apr 21, 2025 |
| Steven Love Other companies: Affymax Inc (Vice President, Finance · Aug 20, 2007 – May 4, 2010 · Past) | Director · Since at least Nov 1, 2023 |
| Amanda N Heravi | Investor Relations Officer · Aug 9, 2021 – Aug 9, 2021 · Past |
| Amechi Nwachuku | Chief Operating Officer · Since at least Jul 13, 2026 |
| Bill Harriman | Sr. Vice President, Discovery Partnership Management, Technology Development and Operations · Since at least Nov 4, 2026 |
| Bob Chen | Sr. Vice President, Discovery Systems · Since at least May 13, 2025 |
| Charles Berkman | Chief Legal Officer · Since at least Apr 7, 2026 |
| Chris Silvia | Vice President, Data Sciences and Corporate IT · Since at least Nov 4, 2026 |
| Christel Iffland | Sr. Vice President, R&D Portfolio Management and Technology Operations · Since at least Nov 5, 2026 |
| Cia McCaffrey | Sr. Vice President, People and Talent · Since at least Nov 5, 2026 |
| Ellen Smith | Associate General Counsel, Intellectual Property and Licensing · Since at least Nov 5, 2026 |
| Joshua Alexander Tamaroff | Director · Nov 1, 2022 – Jun 18, 2024 · Past |
| Neil Castle | Vice President, Biology · Since at least Nov 5, 2026 |
| Robert Girardi | Executive Vice President · Aug 9, 2021 – Aug 9, 2021 · Past |
| Todd Pettingill | Vice President, Business Development and Strategy · Since at least Aug 17, 2026 |
| Yasmina Abdiche | Sr. Vice President, Exploratory Research · Since at least Dec 15, 2025 |
Log in to ask 6ix AI your own questions about OmniAb, Inc.